Revolution Medicines shares promising data around KRAS drug combination

Revolution Medicines' Phase 1 data on combining zoldonrasib with daraxonrasib in pancreatic cancer support a planned Phase 3 trial, as the KRAS field grows more crowded.

Raccontata daendpoints.news